Jeremy Jackson, MD
Dermatology · Jackson, MSNPI 1790996544
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $389,259 of the $450,021 with a category attached, or 86.5%. 35 manufacturers reported payments, led by AbbVie at 30.0% of the total. Reporting peaked in 2019 at $119,396 and has fallen 52.3% since, to $56,979 in 2025. Among dermatology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 626 payments — averaging $718.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$135K
- Janssen Scientific Affairs, LLC$100K
- Johnson & Johnson$70K
- Sanofi$49K
- Novartis$36K
- Pfizer$15K
- plus $44K from 29 others
What the payments were for
- Consulting fees$13,6633%
- Speaking & faculty fees$389,25986%
- Travel & lodging$32,5577%
- Food & beverage$12,9003%
- Education$1,6420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 189 | $135,123 |
| Janssen Scientific Affairs, LLC | 74 | $100,377 |
| Johnson & Johnson | 65 | $69,961 |
| Sanofi | 24 | $48,961 |
| Novartis | 127 | $36,208 |
| Pfizer | 17 | $14,900 |
| DUSA Pharmaceuticals, Inc. | 9 | $11,292 |
| Sun Pharmaceutical Industries Inc. | 15 | $8,894 |
| Helsinn Therapeutics (U.S.), Inc. | 9 | $6,880 |
| Argenx US, Inc. | 6 | $6,830 |
| Boehringer Ingelheim | 7 | $6,783 |
| Dermavant Sciences, Inc. | 1 | $1,445 |
| Mallinckrodt Hospital Products Inc. | 6 | $287 |
| Galderma Laboratories, L.p. | 11 | $284 |
| Kyowa Kirin, Inc. | 5 | $277 |
| UCB, Inc. | 7 | $208 |
| Lilly USA, LLC | 7 | $203 |
| Regeneron Healthcare Solutions, Inc. | 8 | $198 |
| LEO Pharma Inc. | 8 | $177 |
| E.r. Squibb & Sons, L.L.C. | 5 | $121 |
| Organon | 5 | $97 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $83 |
| Almirall LLC | 2 | $76 |
| Arcutis Biotherapeutics, Inc. | 2 | $73 |
| Amgen | 3 | $56 |
| Convatec Inc. | 1 | $33 |
| AstraZeneca(2 entities) | 2 | $33 |
| Bristol Myers Squibb | 2 | $30 |
| Incyte Corporation | 2 | $29 |
| ADC Therapeutics America, Inc. | 1 | $22 |
| Seagen Inc. | 1 | $21 |
| Dova Pharmaceuticals | 1 | $15 |
| Bausch Health US, LLC | 1 | $14 |
| Merck | 1 | $14 |
| Botanix SB Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$450,021 in reported general payments places this provider in the 95th percentile of 78 dermatology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RemicadeInfliximab | 63 | $621,160 |
| Humira(Cf) PenAdalimumab | 37 | $477,364 |
| Skyrizi PenRisankizumab-Rzaa | 19 | $395,000 |
| Dupixent PenDupilumab | 73 | $264,835 |
| Cosentyx Unoready PenSecukinumab | 15 | $183,812 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 21 | $149,797 |
| OtezlaApremilast | 30 | $133,016 |
| InflectraInfliximab-Dyyb | 11 | $111,759 |
| Bexarotene | 20 | $84,774 |
| Humira(Cf)Adalimumab | 13 | $83,440 |
| RinvoqUpadacitinib | 12 | $79,490 |
| Tacrolimus | 33 | $2,040 |
| Clindamycin Phosphate | 42 | $1,664 |
| Clobetasol Propionate | 46 | $1,626 |
| Triamcinolone Acetonide | 95 | $1,556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonRemicade | $69,961 | $621,16063 claims |
| AbbVieHumira(Cf), Rinvoq | $135,123 | $162,92925 claims |
| AmgenOtezla | $56 | $133,01630 claims |
| PfizerInflectra | $14,900 | $111,75911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 78 dermatology providers in Mississippi.
Other dermatology in Jackson
- Thy HuynhJackson$51K
- Robert BrodellJackson$26K
- Colleen PowersJackson$10K
- Ashton DavisJackson$10K
- Carlton DanielJackson$10K
- Caitlyn ReedJackson$6K
- Ashley EmersonJackson$6K
- Summer MorrissetteJackson$4K
- Sarah FillingimJackson$2K
- Julie WyattJackson$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.